OMS824 was well tolerated in the SAD study in which expected pharmacological effects were established in healthy subjects.
The trial was designed to assess the multiple-dose administration of OMS824, a lead compound in phosphodiesterase 10 (PDE10) program. Complete data is expected in 2013.
Omeros chairman and chief executive officer Gregory Demopulos said the company intends to complete Phase 1 trial and commence studies in schizophrenia patients.
"While preparing for the next set of OMS824 studies, our pipeline continues to advance toward additional near-term milestones – Phase 3 data for OMS103HP this month, an NDA submission next quarter and, for as many as three additional programs, entry into the clinic in 2013," Demopulos added.